Investigate how scientific knowledge has led to the development of a technology, including a medical implant or assistive device

What this dot point is asking

NESA wants you to use the cochlear implant as a case study of how scientific knowledge underpins a medical technology, and to evaluate its social, scientific and commercial impact. The cochlear implant is the canonical Australian biomedical case study.

The answer

The multi-channel cochlear implant was developed by Graeme Clark and his team at the University of Melbourne in the 1970s. It restores hearing in profoundly deaf people by directly stimulating the auditory nerve.

The underlying neuroscience

Sound is normally processed in the cochlea, a spiral structure of the inner ear. Approximately 16,000 hair cells line the basilar membrane and respond to different frequencies in a tonotopic arrangement (high frequencies at the base, low at the apex). When sound vibrates the basilar membrane, the hair cells convert mechanical motion into electrical signals carried by the auditory nerve to the brain.

Profoundly deaf people typically have damaged hair cells, but the auditory nerve and brain auditory cortex remain intact. The scientific insight: if electrical signals can directly stimulate the auditory nerve at multiple frequency-specific locations, the brain can interpret them as sound.

Clark's innovation

Earlier single-channel implants (House, USA, 1972) delivered a single frequency to one nerve location. Patients heard a buzz but could not understand speech.

Clark's hypothesis was that multiple electrodes placed along the cochlea, each stimulating frequency-specific nerve fibres, could reproduce the tonotopic organisation and restore speech recognition.

Engineering challenges:

• The cochlea is curved and only 35 mm long.
• 22 electrodes had to be precisely positioned in a flexible array.
• A percutaneous connector had to pass safely through the skull behind the ear.
• A wearable speech processor had to analyse incoming sound in real time and convert it to electrical pulse patterns.

Clark famously prototyped the curved electrode array using a turban shell and a blade of grass to test whether a thin element could be threaded into a spiral structure.

The first surgery

The first multi-channel cochlear implant was placed in Rod Saunders, a profoundly deaf adult, on 1 August 1978 at the Royal Victorian Eye and Ear Hospital, Melbourne. Saunders could recognise speech immediately after the device was switched on.

Commercialisation

In 1981 the technology was licensed to Nucleus Limited (a subsidiary of Telectronics). The Nucleus 22 implant was launched commercially in 1982. The company was reorganised as Cochlear Limited and listed on the ASX in 1995.

Today (2026).

• Cochlear Ltd is an ASX-listed company with market capitalisation around 16 to 20 billion AUD.
• Approximately 60 per cent of global market share.
• Over 700,000 implants placed worldwide.
• Manufacturing in Sydney with 4,000 staff globally.

Impact

For deaf individuals.

• Children implanted before age 2 develop near-normal spoken language.
• Adults with progressive hearing loss can return to phone use, employment and music.

For Australian science.

• The Bionics Institute (founded 1986) and the Hearing Cooperative Research Centre continue to build on Clark's work.
• The Hearing Loop industry and bionic eye research at the University of Melbourne directly descend from cochlear implant engineering.

For medical practice.

• Newborn hearing screening became standard in Australia and many other countries in the 2000s, partly to enable early cochlear implantation.
• The implant inspired subsequent neuroprosthetics, including retinal implants and deep brain stimulators for Parkinson's disease.

Controversies

Deaf community criticism. Some members of the Deaf community criticise the cochlear implant as medicalising deafness, undermining Auslan as a primary language, and de-emphasising Deaf cultural identity. The debate continues about whether to implant deaf children of deaf parents.

Cost and equity. The full implant procedure costs around 30,000 to 50,000 AUD per ear and is partially funded through Medicare and private health. Global access is far less equitable.